Home>
US Stocks>
Abcellera Biologics Inc

Abcellera Biologics Inc share price today

(ABCL)

Abcellera Biologics Inc share price is $2.85 & ₹241.48 as on 6 Dec 2024, 2.30 'hrs' IST

$2.85

▲

-0.05

(-1.72%)

Market is closed - opens 8 PM, 06 Dec 2024

View live Abcellera Biologics Inc share price in Dollar and Rupees. Guide to invest in Abcellera Biologics Inc from India. Also see the sentimental analysis on Indian investors investing in Abcellera Biologics Inc. Get details on the Indian mutual funds that are investing in Abcellera Biologics Inc. Get Analyst recommendations and forecasts along with all the Abcellera Biologics Inc's financials.

Abcellera Biologics Inc share price movements

$2.79
$2.91
$2.85
2.28%
Downside
Day's Volatility :4.3%
Upside
2.06%
$2.34
$6.06
$2.85
18.07%
Downside
52 Weeks Volatility :61.44%
Upside
52.93%

Abcellera Biologics Inc Returns

Period	Abcellera Biologics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	26.78%	-4.7%	0.0%
6 Months	-16.3%	0.9%	0.0%
1 Year	-37.4%	11.6%	0.0%
3 Years	-79.18%	12.9%	-18.1%

Abcellera Biologics Inc Key Statistics

in dollars & INR

Previous Close	$2.9
Open	$2.85
Today's High	$2.91
Today's Low	$2.785
Market Capitalization	$889.1M
Today's Volume	$2.8M
52 Week High	$6.055
52 Week Low	$2.335
Revenue TTM	$33.0M
EBITDA	$-222.2M
Earnings Per Share (EPS)	$-0.61
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.46%
Return On Equity TTM	-15.55%

How to invest in Abcellera Biologics Inc from India?

It is very easy for Indian residents to invest directly in Abcellera Biologics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Abcellera Biologics Inc stock in both rupees (INR) and dollars (USD). Search for Abcellera Biologics Inc or ABCL on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Abcellera Biologics Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Abcellera Biologics Inc shares which would translate to 0.297 fractional shares of Abcellera Biologics Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Abcellera Biologics Inc

43%

Period: Sep 6, 2024 to Dec 5, 2024. Change in 30 Days versus previous period

Search volume for Abcellera Biologics Inc on INDmoney from India has grown in the last 30 days as on Dec 6, 2024. 43% more investors are searching Abcellera Biologics Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Abcellera Biologics Inc

Baker Bros Advisors LP
9.32%
Baillie Gifford & Co Limited.
4.37%
ING Investment Management LLC
3.60%
Prosight Management, LP
3.07%
UBS Asset Mgmt Americas Inc
1.55%
Orbimed Advisors, LLC
1.42%

Analyst Recommendation on Abcellera Biologics Inc

Buy

93%Buy

6%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Abcellera Biologics Inc(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Abcellera Biologics Inc

What analysts predicted

Upside of 331.08%

Current:

$2.85

Target:

$12.29

Insights on Abcellera Biologics Inc

Decreasing Revenue
Revenue is down for the last 3 quarters, 9.95M → 6.50M (in $), with an average decrease of 18.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -36.93M → -51.10M (in $), with an average decrease of 38.4% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 48.5% return, outperforming this stock by 81.2%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 126.0%

Abcellera Biologics Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$8.8M	-
Net Income	$309.0K	-
Net Profit Margin	3.5%	-

	FY19	Y/Y Change
Revenue	$11.6M	↑ 31.49%
Net Income	$-2.4M	↓ 883.14%
Net Profit Margin	-20.84%	↓ 24.34%

	FY20	Y/Y Change
Revenue	$233.2M	↑ 1907.96%
Net Income	$118.9M	↓ 5014.19%
Net Profit Margin	51.0%	↑ 71.84%

	FY21	Y/Y Change
Revenue	$11.6M	↓ 95.02%
Net Income	$-2.2M	↓ 101.86%
Net Profit Margin	-19.04%	↓ 70.04%

	FY22	Y/Y Change
Revenue	$485.4M	↑ 4080.53%
Net Income	$158.5M	↓ 7270.55%
Net Profit Margin	32.66%	↑ 51.7%

	FY23	Y/Y Change
Revenue	$38.0M	↓ 92.17%
Net Income	$-146.4M	↓ 192.35%
Net Profit Margin	-385.0%	↓ 417.66%

	Q2 FY23	Q/Q Change
Revenue	$10.1M	↓ 17.52%
Net Income	$-30.5M	↓ 23.89%
Net Profit Margin	-303.58%	↑ 25.41%

	Q3 FY23	Q/Q Change
Revenue	$6.6M	↓ 34.38%
Net Income	$-28.6M	↓ 6.28%
Net Profit Margin	-433.55%	↓ 129.97%

	Q4 FY23	Q/Q Change
Revenue	$9.2M	↑ 39.1%
Net Income	$-47.2M	↑ 64.8%
Net Profit Margin	-513.67%	↓ 80.12%

	Q1 FY24	Q/Q Change
Revenue	$10.0M	↑ 8.44%
Net Income	$-40.6M	↓ 13.87%
Net Profit Margin	-407.98%	↑ 105.69%

	Q2 FY24	Q/Q Change
Revenue	$7.3M	↓ 26.43%
Net Income	$-36.9M	↓ 9.06%
Net Profit Margin	-504.3%	↓ 96.32%

	Q3 FY24	Q/Q Change
Revenue	$6.5M	↓ 11.14%
Net Income	$-51.1M	↑ 38.39%
Net Profit Margin	-785.42%	↓ 281.12%

	FY18	Y/Y Change
Total Assets	$21.5M	-
Total Liabilities	$9.9M	-

	FY19	Y/Y Change
Total Assets	$23.5M	↑ 9.29%
Total Liabilities	$13.2M	↑ 33.93%

	FY20	Y/Y Change
Total Assets	$1.0B	↑ 4181.05%
Total Liabilities	$175.0M	↑ 1222.37%

	FY21	Y/Y Change
Total Assets	$1.3B	↑ 31.13%
Total Liabilities	$292.8M	↑ 67.31%

	FY22	Y/Y Change
Total Assets	$1.5B	↑ 16.86%
Total Liabilities	$307.6M	↑ 5.05%

	FY23	Y/Y Change
Total Assets	$1.5B	↓ 3.43%
Total Liabilities	$335.8M	↑ 9.15%

	Q2 FY23	Q/Q Change
Total Assets	$1.5B	↑ 2.62%
Total Liabilities	$342.3M	↑ 18.28%

	Q3 FY23	Q/Q Change
Total Assets	$1.5B	↓ 1.62%
Total Liabilities	$329.4M	↓ 3.78%

	Q4 FY23	Q/Q Change
Total Assets	$1.5B	↓ 1.59%
Total Liabilities	$335.8M	↑ 1.93%

	Q1 FY24	Q/Q Change
Total Assets	$1.5B	↓ 1.68%
Total Liabilities	$222.6M	↓ 33.7%

	Q2 FY24	Q/Q Change
Total Assets	$1.4B	↓ 3.46%
Total Liabilities	$177.3M	↓ 20.34%

	Q3 FY24	Q/Q Change
Total Assets	$1.4B	↓ 1.39%
Total Liabilities	$314.7M	↑ 77.49%

	FY18	Y/Y Change
Operating Cash Flow	$3.6M	-
Investing Cash Flow	$-5.3M	-
Financing Cash Flow	$12.2M	-

	FY19	Y/Y Change
Operating Cash Flow	$2.7M	↓ 24.44%
Investing Cash Flow	$-5.8M	↑ 8.91%
Financing Cash Flow	$194.8K	↓ 98.4%

	FY20	Y/Y Change
Operating Cash Flow	$22.7M	↑ 742.33%
Investing Cash Flow	$-119.8M	↑ 1972.35%
Financing Cash Flow	$683.7M	↑ 350804.4%

	FY21	Y/Y Change
Operating Cash Flow	$244.6M	↑ 977.94%
Investing Cash Flow	$-332.2M	↑ 177.38%
Financing Cash Flow	$-3.9M	↓ 100.57%

	FY22	Y/Y Change
Operating Cash Flow	$277.4M	↑ 13.4%
Investing Cash Flow	$-352.6M	↑ 6.13%
Financing Cash Flow	$-1.6M	↓ 58.11%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$19.9M	↓ 145.17%
Investing Cash Flow	$-34.4M	↓ 77.01%
Financing Cash Flow	$419.0K	↓ 191.48%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-106.0K	↓ 100.53%
Investing Cash Flow	$-12.8M	↓ 62.82%
Financing Cash Flow	$6.6M	↑ 1482.34%

Abcellera Biologics Inc Technicals Summary

Sell

Neutral

Buy

Abcellera Biologics Inc is currently in a neutral trading position according to technical analysis indicators.

Abcellera Biologics Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Abcellera Biologics Inc	9.78%	-16.3%	-37.4%	-79.18%	-94.86%
Regeneron Pharmaceuticals, Inc.	-8.09%	-23.99%	-10.23%	20.04%	108.5%
Biontech Se	5.61%	16.8%	14.99%	-61.28%	304.14%
Alnylam Pharmaceuticals, Inc.	-4.63%	65.6%	42.73%	40.34%	109.6%
Vertex Pharmaceuticals Incorporated	-6.83%	-3.58%	31.58%	126.94%	112.3%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Abcellera Biologics Inc	12.33	NA	NA	-0.59	-0.16	-0.13	NA	3.65
Regeneron Pharmaceuticals, Inc.	18.55	18.55	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Abcellera Biologics Inc	Buy	$889.1M	-94.86%	12.33	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	108.5%	18.55	33.61%
Biontech Se	Buy	$28.9B	304.14%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	109.6%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	112.3%	32.84	-4.51%

About Abcellera Biologics Inc

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’

Organization	Abcellera Biologics Inc
Employees	586
CEO	Dr. Carl L.G. Hansen Ph.D.
Industry	Healthcare

Management People of Abcellera Biologics Inc

Name	Title
Dr. Carl L.G. Hansen Ph.D.	CEO, President & Chairperson
Mr. Andrew Booth M.B.A.	Chief Financial Officer
Dr. Veronique Lecault Ph.D.	COO & Director
Mr. Tryn T. Stimart Esq., J.D., M.Sc.	Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer
Marcie Thiessen CPA, CGA	Senior Director of Finance & Accounting
Dr. Ester Falconer Ph.D.	Chief Technology Officer
Kathleen Reid B.A.	Head of Corporate Communications
Graham Craig M.Sc.	Director of Corporate Development
Mr. Murray McCutcheon Ph.D.	Senior Vice President of Partnering
Mr. Neil Aubuchon B.A., M.B.A.	Chief Commercial Officer

Important FAQs about investing in Abcellera Biologics Inc from India :

What is Abcellera Biologics Inc share price today?

Abcellera Biologics Inc (ABCL) share price today is $2.85.

Can Indians buy Abcellera Biologics Inc shares?

Yes, Indians can invest in the Abcellera Biologics Inc (ABCL) from India.

With INDmoney, you can buy Abcellera Biologics Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Abcellera Biologics Inc at zero transaction cost.

How can I buy Abcellera Biologics Inc shares from India?

It is very easy to buy Abcellera Biologics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Abcellera Biologics Inc be purchased?

Yes, you can buy fractional shares of Abcellera Biologics Inc with INDmoney app.

What are the documents required to start investing in Abcellera Biologics Inc stocks?

To start investing in Abcellera Biologics Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.